standards to support health care electronic data interchange, pursuant to P.L. 104–191. Based on those reports, the full Committee is planning to consider its HIPAA recommendations to the Secretary of Health and Human Services. Additional discussions are scheduled on State experiences in implementing health data standards for electronic data interchange and medical records privacy laws and initiatives. A status report also is scheduled on the process for review of OMB Directive 15 on race and ethnicity data. The Committee also will discuss its priorities and work plans.

Contact Person for More Information: Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from James Scanlon, NCVHS Executive Staff Director, Office of the Assistant Secretary for Planning and Evaluation, DHHS, Room 440–D. Humphrey Building, 200 Independence Avenue S.W., Washington, D.C. 20201, telephone (202) 690–7100, or Marjorie S. Greenberg, Acting Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone 301/436–7050.

Dated: June 9, 1997.

James Scanlon,

Director, Division of Data Policy.

[FR Doc. 97–15780 Filed 6–13–97; 8:45 am]

BILLING CODE 4151–04–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Fugang Li, Ph.D., University of Oklahoma Health Sciences Center: Based upon a report from the University of Oklahoma, information obtained by the Office of Research Integrity (ORI) during its oversight review, and Dr. Li's own admission, ORI found that Dr. Li, a former postdoctoral fellow in the Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, engaged in scientific misconduct by fabricating and falsifying data in conducting and reporting research supported by a grant from the National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH).

Specifically, Dr. Li fabricated and falsified data in a study involving the characterization of glycoprotein binding to P-selectin on the surface of human leukocytes. The questioned data were included in a manuscript that was withdrawn prior to publication.

Dr. Li has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed to exclude himself, for the three (3) year period beginning June 3, 1997, from:

(1) Any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 CFR Part 76 (debarment Regulations); and

(2) Serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

No scientific publications were required to be corrected as part of this Agreement.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 97–15758 Filed 6–13–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP); Teleconference Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meetings.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Research Centers/National Center for Chronic Disease Prevention and Health Promotion—General Special Interest Projects, Panel Number 1, Program Announcements 328, 432, 461, and 641.

Time and Date: 1 p.m.–5 p.m., July 7, 1997.

Place: National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, 4770 Buford Highway, NE, Atlanta, Georgia 30345.

Status: Closed.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461, and 641, as announced in Guidance and Consideration in Planning Application for Fiscal Year 1997.

Contact Person for More Information: R. Brick Lancaster, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Atlanta, Georgia 30345. Telephone 770/488–5532.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Research Centers/National Center for Chronic Disease Prevention and Health Promotion—General Special Interest Projects, Panel Number 2, Program Announcements 328, 432, 461, and 641.

Time and Date: 1 p.m.–5 p.m., July 8, 1997.

Place: National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, 4770 Buford Highway, NE, Atlanta, Georgia 30345.

Status: Closed.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461, and 641, as announced in Guidance and Consideration in Planning Application for Fiscal Year 1997.

Contact Person for More Information: Jim Holt, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30341–3724. Telephone 770/488–5595.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Research Centers/National Center for Chronic Disease Prevention and Health Promotion—General Special Interest Projects, Panel Number 3, Program Announcements 328, 432, 461, and 641.

Time and Date: 1 p.m.–5 p.m., July 9, 1997.

Place: National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, 4770 Buford Highway, NE, Atlanta, Georgia 30345.

Status: Closed.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461, and 641, as announced in Guidance and Consideration in Planning Application for Fiscal Year 1997.

Contact Person for More Information: Michael Gay, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30345. Telephone 770/488–5297.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Research Centers/National Center for Chronic Disease Prevention and Health Promotion—General Special Interest Projects, Panel Number 4, Program Announcements 328, 432, 461, and 641.

Time and Date: 1 p.m.–5 p.m., July 10, 1997.

Place: National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, 4770 Buford Highway, NE., Atlanta, Georgia 30345.

Status: Closed.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461, and 641, as announced in Guidance and Consideration in Planning Application for Fiscal Year 1997.

Contact Person for More Information: James E. Barrow, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30345. Telephone 770/488–5269.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Research Centers/ National Center for Chronic Disease Prevention and Health Promotion—General Special Interest Projects, Panel Number 5, Program Announcements 328, 432, 461, and 641.

Time and Date: 1 p.m.–5 p.m., July 11, 1997.

Place: National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, 4770 Buford Highway, NE, Atlanta, Georgia 30345.

Status: Closed.

Matters to Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, 461, and 641, as announced in Guidance and Consideration in Planning Application for Fiscal Year 1997.

Contact Person for More Information: Jim Holt, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30341–3724. Telephone 770/488–5595.

These meetings will be closed to the public in accordance with provisions set forth in section 552b (c)(4) and (6), Title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463.

Dated: June 10, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–15677 Filed 6–13–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members on Public Advisory Committees; Veterinary Medicine Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for members to serve on the Veterinary Medicine Advisory Committee (the committee) in FDA's Center for Veterinary Medicine.

FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees and, therefore, the agency encourages nominations of appropriately qualified candidates from these groups.

DATES: No cutoff date is established for receipt of nominations.

ADDRESSES: All nominations for membership should be sent to Jacquelyn L. Pace (address below).

FOR FURTHER INFORMATION CONTACT: Jacquelyn L. Pace, Center for Veterinary Medicine (HFV–200), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–5920.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for members to serve on the committee. The function of the committee is to review and evaluate available data concerning safety and effectiveness of marketed and investigational new animal drugs, feeds, and devices for use in the treatment and prevention of animal disease and increased animal production.

Criteria for Members

Persons nominated for membership on the committee shall have adequately diversified experience that is appropriate to the work of the committee in such fields as companion animal medicine, food animal medicine, avian medicine, microbiology, biometrics, toxicology, pathology, pharmacology, animal science, epidemiology and chemistry.

The specialized training and experience necessary to qualify the nominee as experts suitable for appointment are subject to review, but may include experience in medical practice, teaching, and/or research relevant to the field of activity of the committee. The term of office is 4 years.

Nomination Procedures

Any interested person may nominate one or more qualified persons for membership on the committee. Nominations shall state that the nominee is aware of the nomination, is willing to serve as a member of the committee, and appears to have no conflict of interest that would preclude committee membership. A current copy of nominee's curriculum vitae should be included. Potential candidates will be asked by FDA to provide detailed information concerning such matters as employment, financial holdings, consultancies, and research grants or contracts in order to permit evaluation of possible sources of conflict of interest.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.

Dated: June 9, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–15636 Filed 6–13–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97D–0214]

Draft Guidance for Industry on Pharmacokinetics and Pharmacodynamics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance entitled ''Pharmacokinetics and Pharmacodynamics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling.'' The draft guidance is intended for sponsors planning to conduct studies to assess the influence of renal impairment on the pharmacokinetics and pharmacodynamics of an investigational drug.

DATES: Written comments may be submitted on the draft guidance by August 15, 1997. General comments on the agency guidance documents are welcome at any time.

ADDRESSES: Submit written requests for single copies of ''Pharmacokinetics and Pharmacodynamics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling'' to the Drug Information Branch (HFD–210), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the guidance to the Dockets Management Branch (HFA–305), Food and Drug